The prognostic impact of the pan-immune-inflammation value (PIV) on the efficacy of treatment and clinical outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC)
Aims: This study aimed to assess the prognostic and predictive implications of pre-treatment pan-immune-inflammation value (PIV) on treatment efficacy and clinical outcomes in patients with extensive-stage small-cell lung cancer (ES-SCLC), comparing it with established indices such as the systemic immune-inflammation index (SII) and neutrophil to lymphocyte ratio (NLR). Methods: A retrospective cohort study included 70 patients diagnosed with ES-SCLC treated with standard chemotherapy with or without immune checkpoint inhibitors. PIV was calculated as PIV=(neutrophils×platelets×monocytes)÷lymphocytes. Patients were categorized into low PIV (
Authors
- Asım Armağan Aydın (ORCID: https://orcid.org/0000-0001-8749-9825)
- Mehmet Acun (ORCID: https://orcid.org/0000-0003-1649-348X)
Institutions
- Sağlık Bilimleri Üniversitesi (TR)
Publication Details
- Journal
- Journal of Health Sciences and Medicine
- Published
- 2024-09-27
- DOI
- https://doi.org/10.32322/jhsm.1489971
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00